Japan grants patent for intralymphatic administration of the diabetes vaccine Diamyd®

The patent now granted by the Japan Patent Office is valid until 2035. Diamyd Medical recently announced the grant of the corresponding patent in Europe. The patents primarily protect the administration method of Diamyd[®] that is now being evaluated in the Phase IIb trial DIAGNODE-2 and which previously showed positive results in the Phase I/II trial DIAGNODE-1.“Having this patent granted in Japan is an important addition to our IP portfolio”, says Ulf Hannelius, CEO of Diamyd Medical. “Japan is one of the largest pharmaceutical markets in the world and the patent will increase our ability